| Issue No. 1 — the Ectoin Moment · Free, no sponsored content, no affiliates. | ||||||||
|
| 01 — The Open |
Morning. A fair amount happened while you weren't looking. Brussels rewrote the ingredient list on half your bathroom shelf. Estée Lauder moved three more brands toward the door. And ectoin, the molecule that's about to be on every jar you pick up this year, finally gets explained by someone who isn't trying to sell it to you. Grab a coffee. This takes five minutes, and nothing here is sponsored.
| In this issue |
| 01 The Open | why a Brussels rule reaches your shelf first |
| 02 The Brief | three things that moved this week |
| 03 The Signal | ectoin, rated by formula not story |
| 04 The Counter | launches you should know about |
| 05 One Good Thing | the one we'd actually keep buying |
| 06 Notes | how we work |
| 02 — The Brief |
Three things that moved this week.
1. The EU just benched twelve ingredients.
In late April the European Commission restricted twelve cosmetic ingredients over concerns about endocrine disruption and genotoxicity (the official name is Regulation (EU) 2026/909, if you like a paper trail). The new limits kick in on 1 January 2027, and anything that doesn't comply has to be off shelves by mid-2028.
Why it matters: Big brands almost never make a separate formula for each country, so a Brussels rule quietly rewrites labels everywhere — London, New York, Dubai — long before anyone local asks them to. So if one of your favourites suddenly gets "improved" this autumn, this is usually why. We're keeping a list of which lines are changing and will name them as the new formulas land.
2. Estée Lauder's clear‑out continues.
Word is the group is reviewing final bids for Too Faced, Smashbox and Dr. Jart+, roughly $3bn of brands it spent the last decade collecting. And it's still buying: it just picked up the Ayurvedic house Forest Essentials in India.
Why it matters: When a brand changes hands, the pattern is pretty reliable. Big discounts first, then a quiet reformulation once the new owner settles in. So if you love something from one of these lines, stock up on the version you know now, and give any "new and improved" label a good year or two of side-eye.
3. Sunscreen science is sprinting, because regulators shrank the toolbox.
At in-cosmetics Paris, the industry's biggest ingredients fair, suppliers told reporters that tighter rules on UV filters in the EU and US are now the single biggest thing pushing sunscreen forward. (Read a recap here)
Why it matters: The next couple of years of SPF launches will be driven by the rulebook, not the marketing team, which means some genuinely new filters and textures for once. We'll tell you which ones are new science and which are just a new bottle.
| 03 — The Signal |
Ectoin, rated by formula not story.
You're going to see this word everywhere this year, so let's get ahead of it. Ectoin is what scientists call an "extremolyte," a molecule that microbes make to survive places nothing should, like salt lakes and deserts. It isn't new. It's been sitting quietly in German pharmacy skincare for about twenty years. So what changed? The whole industry has swung away from harsh actives toward gentler, repair-your-barrier routines, and it needed a poster ingredient. At this spring's big trade fair, "skin stress" was the phrase on everyone's lips, and ectoin fits that story perfectly. That's why it's suddenly on the front of every jar, from the pharmacy own-brand to the prestige counter.
What the people qualified to judge it say
The published studies (a lot of them paid for by the people selling it, which is normal in this industry and worth knowing) point to better moisture retention, calmer redness, and skin that tolerates stronger stuff like retinoids more easily. The independent chemists we trust call it a real, useful ingredient for a stressed or sensitive barrier. Nobody serious is calling it a breakthrough.
Bottom line
A well-earned moment for a good barrier ingredient. Buy it if you want calmer, sturdier skin. Ignore the "longevity" language brands are wrapping around it this year, because that part is wishful thinking. And once you're past about £40, you're paying for the jar, the name and the ritual, not for more ectoin. Which is fine, as long as you know that's the deal.
| 04 — The Counter |
Lancôme × Timeline — Rénergie Nano‑Surgery Cream.
L'Oréal's top-tier brand has licensed Mitopure, the urolithin-A ingredient behind a cult longevity supplement, and built it into a face cream. It's the supplement-world land-grab on skincare in one tidy deal. The catch: Lancôme's own data on the cream is still thin, so read it as a sign of where the expensive end is heading, not proof it works yet. (Linked, not affiliated.)
BL+ (Blue Lagoon) — Cleansing Balm.
Iceland's geothermal-spa brand has put its silica-and-algae complex into a cleansing balm, complete with claims about building collagen. Lovely formulator, this lot. But promising "treatment" results from something you rinse off in ninety seconds is one of the oldest moves in the book. Buy it because it's a great cleanser and leave the collagen talk on the box. (Linked, not affiliated.)
Tatcha — brightening‑longevity run continues.
The Kyoto brand keeps doing its thing, and the postbiotic and NAD+ language it helped popularise is now turning up in cheaper launches about eighteen months later. The trickle-down from posh to high-street is running right on schedule.
| 05 — One Good Thing |
Azelaic acid, 10%.
While everyone chases this year's it-ingredient, the quiet workhorse dermatologists have backed for decades is sitting right there. Azelaic acid takes on redness, uneven tone, rough texture and the odd breakout, it's gentle enough for most sensitive skin, and it starts around £9 / $12. It isn't trendy and it isn't exciting. It just works, over and over. This is the one we'd actually keep buying.
As ever: persistent skin concerns belong with a GP or dermatologist, not an email.
| 06 — Notes |
How we work. No paid write-ups, ever. Sponsors never see a word of our copy before you do, and they get no say in what we cover. When we use an affiliate link, we label it right where you'd click it. Today there aren't any. Spot a mistake, or just want to tell us something? Hit reply. We read everything.
Enjoying this? Forward it to a friend who spends too much on serums.
|